Cargando…

Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood

OBJECTIVE: Prenatal exposure to excess cortisol can affect postnatal metabolic health by epigenetic mechanisms. We aimed to investigate if prenatal exposure to pharmacological glucocorticoids increases the risk of overweight/obesity in childhood. DESIGN: A nationwide population registry-based cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Laugesen, Kristina, Sørensen, Henrik Toft, Jorgensen, Jens Otto L, Petersen, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942335/
https://www.ncbi.nlm.nih.gov/pubmed/35104239
http://dx.doi.org/10.1530/EJE-21-0846
_version_ 1784673287348944896
author Laugesen, Kristina
Sørensen, Henrik Toft
Jorgensen, Jens Otto L
Petersen, Irene
author_facet Laugesen, Kristina
Sørensen, Henrik Toft
Jorgensen, Jens Otto L
Petersen, Irene
author_sort Laugesen, Kristina
collection PubMed
description OBJECTIVE: Prenatal exposure to excess cortisol can affect postnatal metabolic health by epigenetic mechanisms. We aimed to investigate if prenatal exposure to pharmacological glucocorticoids increases the risk of overweight/obesity in childhood. DESIGN: A nationwide population registry-based cohort study. METHODS: We identified 383 877 children born in Denmark (2007–2012), who underwent routine anthropometric evaluation at 5–8 years of age. Prenatal exposure to glucocorticoids was divided into systemic and topical glucocorticoids, cumulative systemic dose, and use by trimester. The comparison cohort included children without exposure, born to maternal never-users. Negative control exposures were used to investigate confounding from an underlying disease or unmeasured characteristics. Such exposures included children without glucocorticoid exposure born to maternal users of non-steroidal anti-inflammatory drugs or immunotherapy during pregnancy, maternal former users of glucocorticoids, or paternal users of glucocorticoids during the pregnancy of their partner. We estimated sex-stratified adjusted prevalence ratios (aPR) of overweight/obesity at 5–8 years of age, as epigenetic modifications have shown to be sex-specific. RESULTS: In the study, 21 246 (11%) boys and 27 851 (15%) girls were overweight/obese at 5–8 years of age. Overall, neither systemic nor topical glucocorticoids were associated with overweight/obesity. In boys, high-dose systemic glucocorticoids was associated with higher prevalence of overweight/obesity vs the comparison cohort (aPR: 1.41 (95% CI: 1.07–1.86), prevalence: 16% vs 11%). Negative control exposures indicated robustness to confounding. CONCLUSION: Overweight/obesity might be an adverse effect of prenatal exposure to high-dose systemic glucocorticoids in boys. We found no association for neither prenatal exposure to lower doses of systemic nor topical glucocorticoids. These results merit clinical attention.
format Online
Article
Text
id pubmed-8942335
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-89423352022-03-28 Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood Laugesen, Kristina Sørensen, Henrik Toft Jorgensen, Jens Otto L Petersen, Irene Eur J Endocrinol Clinical Study OBJECTIVE: Prenatal exposure to excess cortisol can affect postnatal metabolic health by epigenetic mechanisms. We aimed to investigate if prenatal exposure to pharmacological glucocorticoids increases the risk of overweight/obesity in childhood. DESIGN: A nationwide population registry-based cohort study. METHODS: We identified 383 877 children born in Denmark (2007–2012), who underwent routine anthropometric evaluation at 5–8 years of age. Prenatal exposure to glucocorticoids was divided into systemic and topical glucocorticoids, cumulative systemic dose, and use by trimester. The comparison cohort included children without exposure, born to maternal never-users. Negative control exposures were used to investigate confounding from an underlying disease or unmeasured characteristics. Such exposures included children without glucocorticoid exposure born to maternal users of non-steroidal anti-inflammatory drugs or immunotherapy during pregnancy, maternal former users of glucocorticoids, or paternal users of glucocorticoids during the pregnancy of their partner. We estimated sex-stratified adjusted prevalence ratios (aPR) of overweight/obesity at 5–8 years of age, as epigenetic modifications have shown to be sex-specific. RESULTS: In the study, 21 246 (11%) boys and 27 851 (15%) girls were overweight/obese at 5–8 years of age. Overall, neither systemic nor topical glucocorticoids were associated with overweight/obesity. In boys, high-dose systemic glucocorticoids was associated with higher prevalence of overweight/obesity vs the comparison cohort (aPR: 1.41 (95% CI: 1.07–1.86), prevalence: 16% vs 11%). Negative control exposures indicated robustness to confounding. CONCLUSION: Overweight/obesity might be an adverse effect of prenatal exposure to high-dose systemic glucocorticoids in boys. We found no association for neither prenatal exposure to lower doses of systemic nor topical glucocorticoids. These results merit clinical attention. Bioscientifica Ltd 2022-02-01 /pmc/articles/PMC8942335/ /pubmed/35104239 http://dx.doi.org/10.1530/EJE-21-0846 Text en © The authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Clinical Study
Laugesen, Kristina
Sørensen, Henrik Toft
Jorgensen, Jens Otto L
Petersen, Irene
Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title_full Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title_fullStr Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title_full_unstemmed Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title_short Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
title_sort prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942335/
https://www.ncbi.nlm.nih.gov/pubmed/35104239
http://dx.doi.org/10.1530/EJE-21-0846
work_keys_str_mv AT laugesenkristina prenatalexposuretoglucocorticoidsandtheprevalenceofoverweightorobesityinchildhood
AT sørensenhenriktoft prenatalexposuretoglucocorticoidsandtheprevalenceofoverweightorobesityinchildhood
AT jorgensenjensottol prenatalexposuretoglucocorticoidsandtheprevalenceofoverweightorobesityinchildhood
AT petersenirene prenatalexposuretoglucocorticoidsandtheprevalenceofoverweightorobesityinchildhood